Operating Lease, Right-of-Use Asset of Unicycive Therapeutics, Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Unicycive Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • Unicycive Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $249,000, a 68% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Unicycive Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $249,000 -$523,000 -68% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $386,000 -$218,000 -36% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $518,000 -$168,000 -24% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $645,000 -$121,000 -16% 31 Dec 2024 10-Q 12 Nov 2025 2025 Q3
Q3 2024 $772,000 -$73,000 -8.6% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $604,000 -$319,000 -35% 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 $686,000 -$311,000 -31% 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 $766,000 +$614,000 +404% 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $845,000 +$654,000 +342% 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $923,000 +$693,000 +301% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $997,000 +$729,000 +272% 31 Mar 2023 10-Q 16 May 2023 2023 Q1
Q4 2022 $152,000 -$153,000 -50% 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $191,000 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $230,000 30 Jun 2022 10-Q 15 Aug 2022 2022 Q2
Q1 2022 $268,000 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $305,000 31 Dec 2021 10-K 31 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.